Article Trunk



Chemistry / M2 Pharma, “Novartis Survey of Immune Thrombocytopenia Patients Yields Quality of Life Concerns.”

06.21.2018 · Posted in Uncategorized
M2 PHARMA-June 21, 2018-Novartis Survey of Immune Thrombocytopenia Patients Yields Quality of Life Concerns (C)2018 M2 COMMUNICATIONS
  • East Hanover, New Jersey-based healthcare solutions provider Novartis Pharmaceuticals Corp. has found that many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on everyday quality of life,...

Leave a Reply

You must be logged in to post a comment.

%d bloggers like this: